Trial Profile
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2020
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PANORAMA 2; PANORAMA-II
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 06 Nov 2014 According to a Novartis media release, the FDA Oncologic Drugs Advisory Committee did not recommend panobinostat for previously treated multiple myeloma.
- 04 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.